Aymeric Ravel-Chapuis

Dr. Aymeric Ravel-Chapuis

Co-Applicant

Assistant Professor in the School of Pharmaceutical Sciences at the University of Ottawa


NMD4C Involvement: Pillar 1: Preclinical Science

Email Aymeric

Research Interests: Neuromuscular disorders, Myotonic Dystrophy, Cell signaling, Post-transcriptional regulations, Myosecretome, Novel therapeutic strategies

Academic web profile
Google Scholar profile
ORCiD profile

Biography

Dr. Ravel-Chapuis is an Assistant Professor in the School of Pharmaceutical Sciences at the University of Ottawa. He received his PhD from the Ecole Normale Supérieure de Lyon (France), focusing on the role of epigenetic modifications as regulators of gene expression in skeletal muscle. He next completed a postdoctoral fellowship at the University of Ottawa, studying the involvement of RNA-binding proteins in Myotonic Dystrophy type 1 (DM1).  Subsequently, he pursued his research as a research associate, characterizing cell signaling dysfunction in DM1 and developing new pharmacological approaches to improve the disease phenotype. In 2022, Dr. Ravel-Chapuis started a new independent research program at the University of Ottawa, investigating the role of the myosecretome in the context of DM1 and other neuromuscular disorders.


Recent Publications

Ravel-Chapuis, A, Fahmi, C, Gobin, J, Jasmin, BJ. The AMPK allosteric activator MK-8722 improves the histology and spliceopathy in myotonic dystrophy type 1 (DM1) skeletal muscle. FASEB J. 2024.38 (23)e70199 PMID:39611312

Roussel, MP, Ravel-Chapuis, A, Gobin, J, Jasmin, BJ, Leduc-Gaudet, JP, Gagnon, C et al.. Changes in Physiopathological Markers in Myotonic Dystrophy Type 1 Skeletal Muscle: A 3-Year Follow-up Study. J Neuromuscul Dis. 2024.11 (5)981-995 PMID:39031377

Neault, N, Ravel-Chapuis, A, Baird, SD, Lunde, JA, Poirier, M, Staykov, E et al.. Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse Model. Int J Mol Sci. 2023.24 (4) PMID:36835205

Osseni, A, Ravel-Chapuis, A, Belotti, E, Scionti, I, Gangloff, YG, Moncollin, V et al.. Pharmacological inhibition of HDAC6 improves muscle phenotypes in dystrophin-deficient mice by downregulating TGF-β via Smad3 acetylation. Nat Commun. 2022.13 (1)7108 PMID:36402791

van Cruchten, RTP, van As, D, Glennon, JC, van Engelen, BGM, 't Hoen, PAC, OPTIMISTIC consortium et al.. Clinical improvement of DM1 patients reflected by reversal of disease-induced gene expression in blood. BMC Med. 2022.20 (1)395 PMID:36352383

Misquitta, NS, Ravel-Chapuis, A, Jasmin, BJ. Combinatorial treatment with exercise and AICAR potentiates the rescue of myotonic dystrophy type 1 mouse muscles in a sex-specific manner. Hum Mol Genet. 2023.32 (4)551-566 PMID:36048859

Freeman, E, Langlois, S, Scott, K, Ravel-Chapuis, A, Jasmin, BJ, Cowan, KN et al.. Sex-dependent role of Pannexin 1 in regulating skeletal muscle and satellite cell function. J Cell Physiol. 2022.237 (10)3944-3959 PMID:35938715

Ravel-Chapuis, A, Duchesne, E, Jasmin, BJ. Pharmacological and exercise-induced activation of AMPK as emerging therapies for myotonic dystrophy type 1 patients. J Physiol. 2022.600 (14)3249-3264 PMID:35695045

Ravel-Chapuis, A, Jasmin, BJ. Combinatorial therapies for rescuing myotonic dystrophy type 1 skeletal muscle defects. Trends Mol Med. 2022.28 (6)439-442 PMID:35537989

Ravel-Chapuis, A, Haghandish, A, Daneshvar, N, Jasmin, BJ, Côté, J. A novel CARM1-HuR axis involved in muscle differentiation and plasticity misregulated in spinal muscular atrophy. Hum Mol Genet. 2022.31 (9)1453-1470 PMID:34791230

See more on PubMed